News

– Virtual investor event to take place on Monday, June 7, 2021 at 6 p.m. ET – SHANGHAI, China , and REDWOOD CITY, Calif. , June 04, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co. , Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc.

– In pivotal Phase 3 JUPITER-02 study, toripalimab plus chemotherapy significantly improved PFS compared to chemotherapy alone in high and low PD-L1 expression subgroups – –  Although median overall survival (OS) analysis was not yet mature, a 40% reduction in risk of death was observed in the

REDWOOD CITY, Calif. , May 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming Bank of America Health Care Conference on Wednesday, May 12, 2021 at 1:15 p.m. EST / 10:15 a.m. PST .

– Junshi Biosciences transaction is followed by rapid toripalimab progress including initiation of first BLA submission to the U.S. FDA, positive interim analysis in pivotal esophageal cancer trial, and selection for ASCO plenary session – –Toripalimab is one of four additional Coherus product

REDWOOD CITY, Calif. , April 30, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective April 28, 2021 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 483,000 shares

REDWOOD CITY, Calif. , April 30, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its first quarter 2021 financial results will be released after market close on Thursday, May 6, 2021 . Starting at 4:30 p.m.

- Toripalimab data will also be featured in ASCO’s official press program - SHANGHAI, China , and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co. , Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and  Coherus BioSciences, Inc.  (“Coherus”, Nasdaq:

REDWOOD CITY, Calif. , April 23, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring Committee of the JUPITER-06 clinical trial has determined that toripalimab, an anti-PD-1

Coherus received $50 million from sale of 2,491,998 shares at $20.06 per share REDWOOD CITY, Calif. , April 20, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced the closing of the sale of Coherus common stock to Junshi Biosciences.

- BLA submitted with FDA’s breakthrough therapy designation – SHANGHAI, China , and REDWOOD CITY, Calif. , March 03, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc.

REDWOOD CITY, Calif. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in March. 41 st Annual Cowen Healthcare Conference on Monday, March 1 at 4 p.m.

- Product revenues of $476 million for full year 2020, $110 million for the fourth quarter of 2020 -  - Expanding late-stage opportunities with Junshi Biosciences immuno-oncology collaboration with first BLA filing expected this year -  - Pipeline progress with CHS-1420 (adalimumab biosimilar) BLA

REDWOOD CITY, Calif. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that it will release fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021.

REDWOOD CITY, Calif. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) has accepted for review the 351(k) Biologics License Application (“BLA”) for CHS-1420, a Humira®

REDWOOD CITY, Calif. , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that Chief Financial Officer Jean-Frédéric Viret, Ph.D. will resign from Coherus effective March 7, 2021 to pursue another opportunity.

REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) (“Coherus”) announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) (“Junshi Biosciences”) intends to make a strategic

- Coherus to pay $150 million upfront for U.S. and Canada rights to toripalimab, an extensively studied, late-stage anti-PD-1 antibody - First U.S. BLA filing expected this year for nasopharyngeal carcinoma with breakthrough therapy designation - Options to PD-1 combination agents, TIGIT and IL-2,

REDWOOD CITY, Calif. , Jan. 22, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective January 21, 2021 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 60,000 shares

REDWOOD CITY, Calif. , Jan. 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointments of Alan C. Mendelson and Mark D. Stolper to its Board of Directors effective January 5, 2021 .  “We are excited to welcome Alan and Mark to the Coherus

REDWOOD CITY, Calif. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 39 th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. EST / 7:50 a.m. PST .